78288-94-5

Usage

Uses

Used in Pharmaceutical Industry:
7-Nitro-3,4-dihydro-2H-1,5-benzodioxepine is utilized as a pharmaceutical intermediate for the synthesis of various drug candidates. Its unique structure and potential biological activity make it a valuable compound in the development of new medications, particularly those targeting specific therapeutic areas.
Used in Research and Development:
In the field of scientific research, 7-Nitro-3,4-dihydro-2H-1,5-benzodioxepine serves as a key compound for exploring its chemical properties and potential interactions with biological systems. It is used to investigate its role in medicinal chemistry and to understand how it can be modified or combined with other compounds to create novel therapeutic agents.
Used in Drug Design and Synthesis:
7-Nitro-3,4-dihydro-2H-1,5-benzodioxepine is employed as a building block in the design and synthesis of new drugs. Its chemical structure provides a foundation for the creation of innovative pharmaceuticals, with the nitro group and benzodioxepine core offering opportunities for functionalization and optimization to enhance drug efficacy and safety.
While the specific applications of 7-Nitro-3,4-dihydro-2H-1,5-benzodioxepine in different industries are not explicitly detailed in the provided materials, the general uses outlined above are based on the compound's potential in the pharmaceutical sector and its role in research and development. Further studies and investigations are necessary to fully understand its capabilities and to explore additional applications across various industries.

InChI:InChI=1/C9H9NO4/c11-10(12)7-2-3-8-9(6-7)14-5-1-4-13-8/h2-3,6H,1,4-5H2

Upstream product

• 7216-18-4 3,4-dihydro-2H-benzo[b][1,4]dioxepine 
• 3316-09-4 1,2-dihydroxy-4-nitrobenzene 
• 109-64-8 1,3-dibromo-propane 

Downstream Products

• 175136-34-2 3,4-dihydro-7-amino-2H-1,5-benzo[b][1,4]dioxepin 
• 33631-94-6 3,4-dihydro-7-acetamido-2H-1,5-benzodioxepin 

Relevant academic research and scientific papers

Guanidine compound for preventing and treating chronic pain medication (by machine translation)

The invention relates to a guanidine compound as shown in general formula (I) as a guanidine compound for preventing and treating chronic pain disease. A pharmaceutically acceptable salt thereof, a prodrug thereof, a solvate thereof, a deuterated substanc

BENZOFUROPYRAZOLE DERIVATIVE

PROBLEM TO BE SOLVED: To provide a novel material having HIF inhibitory activity. SOLUTION: The present invention provides a compound represented by the following general formula (I) [where R1, R2, R3, and R4 each represent a hydrogen atom, a methoxy group, an ethoxy group, a hydroxy group, an N-morpholylurea group, or an N-(4-aminophenyl) urea group, or adjacent ones of them bind together to form an alkylenedioxy group; R5, R6, R7, R8, and R9 each represent a hydrogen atom, a methoxy group, a hydroxy group, a methoxy carbonyl group, a carboxyl group, an isopropyl group, or an isobutoxy group, or adjacent ones of them bind together to form an alkylenedioxy group]. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

Exploring Epidermal Growth Factor Receptor (EGFR) inhibitor features: The role of fused dioxygenated rings on the quinazoline scaffold

A number of dioxolane, dioxane, and dioxepine quinazoline derivatives have been synthetized, and evaluated as EGFR inhibitors. Their cytotoxic activity has been tested against two cell, lines overexpressing and not expressing EGFR. Most derivatives were a

Synthesis and crystal structure of 3, 4-dihydro-7-acetamido-2H-1,5-benzodioxepine

The synthesis of 3,4-dihydro-7-acetamido-2H-1,5-benzodioxepin III is achieved starting from 3,4-dihydro-7-nitro-benzodioxepin II. The new acetamid prepared is characterized by spectroscopic technics, IR; UV; 1H-NMR; 13C-NMR; mass spectrometry and by XR diffraction. A monocrystal from the product is selected and its crystal structure resolved. The solid crystallizes in orthorhombic system with space group Pcab. The crystal cohesion is assumed by hydrogen bonds and Vander-Waals interactions.

Influence of the Heterocyclic Side Ring on Orientation During Nitrations of 1,2-Alkylenedioxy-annelated Benzenes and Their Mononitro Derivatives

Nitration of 1,2-alkylenedioxybenzenes 1 furnished the respective nitro derivatives 3 and 4 in the relative ratios: 4a:3a/100:trace, 4b:3b/98:2.4, 4c:3c/86:14, 4e:3e/91:9, 4f:3f/99:1.3.Nitration of 4 gave 5a:6a:8a/0:0:100, 5b:6b:8b/7.7:3.2:89, 5c:6c:8c/23:12:65, 5d:6d:8d/14:74:12, 5e:6e:8e/27:18:55 and 5f:6f:8f/23:7.0:70.Nitration of the isomeric 3 afforded the dinitroproducts 5, 6 and 7 in the following relative ratios: 5a:6a:7a/92:8:0, 5b:6b:7b/80:20:0, 5c:6c:7c/69:20:11, 5d:6d:7d/45:19:36, 5e:6e:7e/37:57:5.9 and 5f:6f:7f/64:36:0.Nitration of 3-nitro-1,2-dimethoxybenzene (9) furnished: 10:11/63:37.Orientation as a function of the h eterocyclic ring-size is discussed.